mRESVIA RSV vaccine approved to protect patients aged 60 and over, UK News and communications
mRESVIA RSV Vaccine Approved in the UK to Protect Adults Aged 60 and Over London, UK – 2025-02-28, 10:31 GMT – In a significant step forward in preventative healthcare, the UK’s regulatory body has approved mRESVIA, a new vaccine specifically designed to protect adults aged 60 and over from Respiratory Syncytial Virus (RSV). The announcement, … Read more